Form 4: Exelixis GC Brenda Hefti Granted 23,119 RSUs

Exelixis' SVP and General Counsel, Brenda Hefti, was granted 23,119 restricted stock units on February 26, 2026, as part of the company's equity incentive plan.

Summary

• Brenda Hefti, SVP and General Counsel of Exelixis, Inc., received a grant of 23,119 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on February 26, 2026, with a price of $0, indicating an equity award.
• These RSUs will vest in installments: 1/4th of the original number of shares on May 15, 2027, and 1/4th on each subsequent May 15th until fully vested.
• Following this transaction, Brenda Hefti directly beneficially owns 119,631 shares, which includes 119,075 shares from RSUs and performance-based restricted stock unit awards.
• Additionally, 5,527 shares are indirectly owned through the Exelixis, Inc. 401(k) Plan.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and retention efforts, which are standard practice and align management incentives with shareholder interests.

Positives

• Grant of 23,119 Restricted Stock Units (RSUs) to a key executive, aligning management's interests with shareholder value.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged trading plan.

Future Outlook

The newly granted Restricted Stock Units (RSUs) will vest in four equal annual installments, beginning on May 15, 2027, and continuing on each subsequent May 15th until fully vested.

Industry Context

StockSavvy.ai notes that equity grants like RSUs are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and retention. This aligns the executive's financial interests with the company's stock performance.

Comparison to Industry Standards

• Equity compensation, particularly through Restricted Stock Units (RSUs), is a common practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedule, typically over several years, is standard for retaining key talent and aligning executive incentives with long-term shareholder value creation, similar to plans observed at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Aligns executive interests with shareholder value through equity ownership and long-term vesting.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Vesting of 1/4th of the granted RSUs on May 15, 2027.
• Subsequent annual vesting of 1/4th of the RSUs on each May 15th until fully vested.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to an executive, which is a standard part of compensation and retention. It does not present new information that would fundamentally alter the investment thesis for Exelixis, hence a "hold" recommendation is appropriate for existing investors. New investors would need to consider broader company fundamentals.

Keywords

Exelixis, EXEL, Brenda Hefti, Form 4, RSU, Restricted Stock Units, Equity Incentive Plan, Executive Compensation, Insider Transaction, 10b5-1